Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLI NASDAQ:MGTX NASDAQ:NAMS NYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$21.93-1.3%$19.86$12.58▼$23.77$3.53B1.031.79 million shs1.46 million shsMGTXMeiraGTx$9.71-0.4%$9.63$6.07▼$11.85$902.94M1.26786,361 shs499,947 shsNAMSNewAmsterdam Pharma$30.19-1.3%$33.34$17.63▼$42.21$3.58B0.071.21 million shs1.16 million shsOGNOrganon & Co.$13.43-0.1%$11.90$5.69▼$13.49$3.53B1.552.60 million shs2.59 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+2.59%+13.72%+19.33%+7.29%+52.71%MGTXMeiraGTx+1.67%+7.26%+3.72%+27.45%+47.06%NAMSNewAmsterdam Pharma+0.66%-1.13%-13.66%0.00%+51.41%OGNOrganon & Co.0.00%+0.52%+0.45%+110.73%+34.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$21.93-1.3%$19.86$12.58▼$23.77$3.53B1.031.79 million shs1.46 million shsMGTXMeiraGTx$9.71-0.4%$9.63$6.07▼$11.85$902.94M1.26786,361 shs499,947 shsNAMSNewAmsterdam Pharma$30.19-1.3%$33.34$17.63▼$42.21$3.58B0.071.21 million shs1.16 million shsOGNOrganon & Co.$13.43-0.1%$11.90$5.69▼$13.49$3.53B1.552.60 million shs2.59 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+2.59%+13.72%+19.33%+7.29%+52.71%MGTXMeiraGTx+1.67%+7.26%+3.72%+27.45%+47.06%NAMSNewAmsterdam Pharma+0.66%-1.13%-13.66%0.00%+51.41%OGNOrganon & Co.0.00%+0.52%+0.45%+110.73%+34.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 2.87Moderate Buy$34.2556.18% UpsideMGTXMeiraGTx 2.75Moderate Buy$25.83166.05% UpsideNAMSNewAmsterdam Pharma 2.83Moderate Buy$48.6060.98% UpsideOGNOrganon & Co. 1.71Reduce$11.40-15.08% DownsideCurrent Analyst Ratings BreakdownLatest MGTX, OGN, DNLI, and NAMS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2026DNLIDenali Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/26/2026MGTXMeiraGTx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/15/2026OGNOrganon & Co. Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/15/2026MGTXMeiraGTx Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$24.00 ➝ $25.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.005/11/2026DNLIDenali Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/8/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.004/29/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Neutral$12.00 ➝ $14.004/28/2026OGNOrganon & Co. BNP Paribas ExaneSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M10.53N/AN/A$6.91 per share3.17MGTXMeiraGTx$81.39M11.05N/AN/A($0.07) per share-138.71NAMSNewAmsterdam Pharma$22.50M156.85N/AN/A$5.97 per share5.06OGNOrganon & Co.$6.22B0.57$5.79 per share2.32$2.89 per share4.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)MGTXMeiraGTx-$114.20M-$1.48N/AN/AN/A-151.12%-1,065.47%-54.96%8/13/2026 (Estimated)NAMSNewAmsterdam Pharma-$203.82M-$1.79N/AN/AN/A-943.23%-26.49%-24.37%8/5/2026 (Estimated)OGNOrganon & Co.$187M$0.9314.443.901.243.99%99.95%6.22%8/4/2026 (Estimated)Latest MGTX, OGN, DNLI, and NAMS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026MGTXMeiraGTx-$0.6060-$0.57+$0.0360-$0.57$17.00 million$0.29 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/7/2026Q1 2026NAMSNewAmsterdam Pharma-$0.46-$0.40+$0.06-$0.40$1.75 million$3.04 million4/30/2026Q1 2026OGNOrganon & Co.$0.83$0.71-$0.12$0.55$1.49 billion$1.46 billion3/31/2026Q1 2026NAMSNewAmsterdam PharmaN/A-$0.40N/A-$0.40N/A$3.04 million3/26/2026Q4 2025MGTXMeiraGTx-$0.60$0.19+$0.79$0.19$3.87 million$75.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ANAMSNewAmsterdam PharmaN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.60%N/A8.60%N/ALatest MGTX, OGN, DNLI, and NAMS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2026OGNOrganon & Co.quarterly$0.020.6%5/11/20265/11/20266/11/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali Therapeutics0.019.289.28MGTXMeiraGTxN/A0.550.55NAMSNewAmsterdam PharmaN/A9.769.76OGNOrganon & Co.9.471.971.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%MGTXMeiraGTx67.48%NAMSNewAmsterdam Pharma89.89%OGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics12.50%MGTXMeiraGTx7.40%NAMSNewAmsterdam Pharma12.74%OGNOrganon & Co.1.62%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableMGTXMeiraGTx30092.61 million85.76 millionOptionableNAMSNewAmsterdam Pharma4116.90 million102.01 millionOptionableOGNOrganon & Co.10,000262.60 million258.35 millionNot OptionableMGTX, OGN, DNLI, and NAMS HeadlinesRecent News About These CompaniesOrganon & Co. (NYSE:OGN) Receives Consensus Recommendation of "Reduce" from AnalystsJune 15 at 4:27 AM | americanbankingnews.comOrganon & Co. (NYSE:OGN) vs. Natera (NASDAQ:NTRA) Financial SurveyJune 13 at 2:10 AM | americanbankingnews.comOrganon Wins FDA Nod to Expand TOFIDENCE Use in Severe CRS & COVID-19June 12, 2026 | zacks.comSector Gamma AS Has $2.15 Million Stock Position in Organon & Co. $OGNJune 12, 2026 | marketbeat.comPrivate Management Group Inc. Acquires 1,204,979 Shares of Organon & Co. $OGNJune 12, 2026 | marketbeat.comOrganon & Co. (NYSE:OGN) Sets New 1-Year High - Still a Buy?June 11, 2026 | marketbeat.comBrandes Investment Partners LP Has $4.35 Million Stock Holdings in Organon & Co. $OGNJune 11, 2026 | marketbeat.comOrganon wins US approval to widen use of arthritis biosimilar drugJune 10, 2026 | reuters.comOrganon & Co. (NYSE:OGN) Given Consensus Rating of "Reduce" by BrokeragesJune 10, 2026 | marketbeat.comOrganon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on ItJune 9, 2026 | zacks.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Organon & Co. (OGN)June 2, 2026 | newsfilecorp.comNInvestors Heavily Search Organon & Co. (OGN): Here is What You Need to KnowMay 29, 2026 | zacks.comOrogen Reports Strong Q1 2026 Results with 144% Growth in Net IncomeMay 26, 2026 | accessnewswire.comALSV Asset Management Lowers Stock Position in Organon & Co. $OGNMay 25, 2026 | marketbeat.comHanmi Pharmaceutical Partners with Organon to Export Combination Therapies to Southeast AsiaMay 21, 2026 | globenewswire.comPoehling Capital Management INC. Sells 101,256 Shares of Organon & Co. $OGNMay 20, 2026 | marketbeat.comOrganon & Co. (OGN) is Attracting Investor Attention: Here is What You Should KnowMay 18, 2026 | zacks.comDeep value mid-caps: 10 names trading at single-digit forward P/EsMay 18, 2026 | seekingalpha.comOrganon to Present New Research on Access and Value at ISPOR 2026May 15, 2026 | businesswire.comOrganon Buyout By Sun Pharma Shifts Focus To Cash Value And TimingMay 8, 2026 | finance.yahoo.comOrganon & Co. (NYSE:OGN) SVP Lynette Holzbaur Buys 26,448 SharesMay 8, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMGTX, OGN, DNLI, and NAMS Company DescriptionsDenali Therapeutics NASDAQ:DNLI$21.93 -0.29 (-1.31%) Closing price 04:00 PM EasternExtended Trading$21.82 -0.11 (-0.48%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.MeiraGTx NASDAQ:MGTX$9.71 -0.04 (-0.41%) Closing price 04:00 PM EasternExtended Trading$9.71 0.00 (0.00%) As of 05:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.NewAmsterdam Pharma NASDAQ:NAMS$30.19 -0.41 (-1.34%) Closing price 04:00 PM EasternExtended Trading$30.18 -0.01 (-0.02%) As of 04:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Organon & Co. NYSE:OGN$13.42 -0.02 (-0.11%) Closing price 03:59 PM EasternExtended Trading$13.41 -0.02 (-0.11%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Gravity Check: Houston, SpaceX Has a Valuation Problem Okta’s AI Moment May Be Bigger Than Investors Realize Strategy’s Bitcoin Rally Has a Hidden Engine Is Lennar Finally Turning the Corner After Its Housing Slump? Plot Twist: How the $110B Paramount-Warner Deal Rewrites Media AST SpaceMobile Announces Launch Date for Its Next 3 BlueBird Satellites Insiders Sell Top Tech Plays: Should Investors Buy, Sell, or Hold? What's Behind the Social Media Controversy Surrounding IonQ? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
